Benzinga's Microcap Movers for Thursday June 14, 2012
Below are highlights from Benzinga's daily coverage of microcap securities making big moves:
First Liberty Power
First Liberty Power (FLPC), the Las Vegas, NV mining company, rose 63.33% Thursday on 44 times the average daily volume.
First Liberty Power announced on Wednesday that it has entered into a purchase agreement with GeoXplor Corp. for 70 placer claims totaling 11,200 acres, located in Smokey Valley, Esmeralda County, Nevada.
On Thursday, First Liberty issued its 10-Q. As of April 30, 2012, cash balance was $109,327, which is an increase from cash balance of $74,576 at July 31, 2011. This net increase in cash ensued from the closing of two convertible notes in March and April of 2012, of which the net proceeds to the Company were $180,000. The Company's cash position is insufficient to meet its obligations through to the end of the fiscal year.
First Liberty Power closed at $0.0490 on Thursday.
Shares of Complete Genomics (NASDAQ: GNOM), the Mountain View, CA human genome sequencing and analysis company, rose 12.85% Thursday on average volume.
An article in Bloomberg mentioned that genome screening could be an "early warning system" to indicate cancer risks in healthy people.
Complete Genomics closed at $2.02 on Thursday.
Shares of Biostar Pharmaceuticals (NASDAQ: BPSM), the China-based manufacturer and marketer of pharmaceutical and health supplement products, rose 15.56% Thursday on almost 13 times the average daily volume.
Biostar Pharmaceuticals announced Wednesday that it signed a Letter of Intent with The Fourth Military Medical University to jointly conduct Phases I to III clinical trials for Viacom Pine II Cream drug. The LOI has been submitted to China's military authorities for approval.
Biostar Pharmaceuticals closed at $1.70 on Thursday.
The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment. Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.